Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, announces that the U.S. Food and Drug A...
Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and...
Amarna Therapeutics, (“Amarna” or “the Company”), a privately held biotechnology company pioneering transformative gene therapies...
Orchard Therapeutics, a Kyowa Kirin company, announced the last patient has been treated in a registrational trial evaluating the efficacy and safety of ...
PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery techn...
ProBio, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, today announced the opening of its...
Bristol Myers Squibb’s announcement that the US Food and Drug Administration has approved the removal of REMS programs an...
Invetech, a global leader in solving complex manufacturing and product development challenges in the advanced therapies and diagnostics markets, today an...
AGC Biologics, your friendly CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc....
CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO) specialized in Advanced Therapy Medicinal Products (ATMPs...
First patient received bilateral administration of NRTX-1001; no significant surgical complications or adverse events reported to date - - Trial funded...
Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP),...
SynaptixBio, the only company licensed to commercialise a treatment for a rare, deadly disease, says the drug could halt disease progression and even rever...
-SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Ther...
© 2025 Biopharma Boardroom. All Rights Reserved.
